drugset / Trial / NCT03769805
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Unknown
83 enrolled
The First Affiliated Hospital with Nanjing Medical University
Huai'an First People's Hospital · collabJiangsu Taizhou People's Hospital · collabThe Affiliated Hospital of Xuzhou Medical University · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabYancheng City NO.1 People's Hospital · collabZhongda Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride versus pemetrexed in maintenance therapy for advanced NSCLC to prospectively evaluate the efficacy of antinil hydrochloride in maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging the survival time of patients with advanced NSCLC, improving the quality of life of patients in the course of treatment, and optimizing treatment strategies to a greater extent.
Timeline
- Start
- 2019-06-15
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |